Peptide Hormones in Menopause: The Full Cascade
Menopause and Peptide Hormones
15× FSH increase
Follicle-stimulating hormone rises up to 15-fold after menopause as ovarian inhibin and estrogen feedback collapse, triggering cascading changes across dozens of peptide systems.
Endocrinology of the Menopause, PMC, 2020
Endocrinology of the Menopause, PMC, 2020
View as imageMenopause is not a single hormonal event. It is a cascade that begins in the hypothalamus and ripples outward through every peptide-signaling system in the body. The obvious changes (estrogen and progesterone decline) are steroid hormones, not peptides. But the peptide hormones that regulate, respond to, and compensate for that steroid decline are where much of the clinical story plays out: the 15-fold rise in FSH, the collapse of anti-Mullerian hormone (AMH) years before the final period, the hypertrophy of kisspeptin neurons driving hot flashes, and the bone peptide shifts that set up postmenopausal osteoporosis.
This pillar article maps the full peptide hormone cascade of menopause. For specific therapeutic applications, see the dedicated articles on fezolinetant and neurokinin B antagonism for hot flashes, kisspeptin and vasomotor symptoms, and peptide alternatives to hormone replacement therapy.
Key Takeaways
- FSH rises up to 15-fold and LH up to 10-fold in early postmenopause as ovarian inhibin and estrogen feedback collapse
- AMH becomes undetectable 5-10 years before the final menstrual period, making it the earliest peptide biomarker of ovarian aging
- Hypothalamic KNDy neurons (kisspeptin/neurokinin B/dynorphin) hypertrophy after menopause, with increased NKB and kisspeptin expression driving both gonadotropin surges and hot flashes[1]
- Postmenopausal growth hormone secretion drops approximately 14% per decade, accelerated by estrogen loss disrupting the GHRH-ghrelin peptide drive[10]
- Neuropeptides SP, CGRP, VIP, and NPY shift in bone tissue after menopause, correlating with osteoporosis severity[7]
- Fezolinetant, a neurokinin B receptor antagonist, became the first non-hormonal peptide-targeted drug approved for menopausal hot flashes (FDA 2023)
The Hypothalamic Control Center: GnRH, Kisspeptin, and KNDy Neurons
The menopausal cascade begins not in the ovaries but in the hypothalamus, where gonadotropin-releasing hormone (GnRH) neurons receive inputs from a specialized population called KNDy neurons. These cells co-express three peptides: kisspeptin (stimulatory), neurokinin B (stimulatory), and dynorphin (inhibitory).[3] Together, they form the pulse generator that dictates GnRH release frequency and, through it, the entire reproductive hormone axis.
Before menopause, ovarian estrogen and progesterone exert negative feedback on KNDy neurons, keeping kisspeptin and neurokinin B expression in check and maintaining dynorphin's inhibitory tone.[1] As ovarian follicle reserves dwindle and steroid output drops, this brake releases. Autopsy studies of postmenopausal women show that KNDy neurons physically enlarge (hypertrophy) and increase their expression of neurokinin B and kisspeptin while decreasing dynorphin.[5]
The result: GnRH pulse frequency increases from approximately every 90 minutes to every 55 minutes. GnRH pulse amplitude also rises. This accelerated pulsing drives the pituitary to produce dramatically more FSH and LH, the hallmark hormonal signature of menopause.
A 2022 review in Peptides translated this basic biology into clinical context: the same neurokinin B surges driving elevated GnRH also activate thermoregulatory neurons in the adjacent preoptic area of the hypothalamus, producing hot flashes.[2] This mechanism is why neurokinin B receptor antagonists like fezolinetant can treat hot flashes without replacing estrogen. The NKB-thermoregulatory connection also explains why hot flashes correlate with LH pulses in many women: both are downstream of the same KNDy neuron hyperactivity.
Neurokinin B also projects directly from the arcuate nucleus to magnocellular vasopressin cells, linking the reproductive peptide cascade to fluid balance and blood pressure regulation.[6] This connection may partly explain why hypertension risk increases after menopause through mechanisms beyond estrogen withdrawal alone.
Pituitary Peptide Hormones: FSH, LH, and the Gonadotropin Surge
The most dramatic peptide changes of menopause occur at the pituitary. With reduced ovarian negative feedback, FSH rises up to 15-fold and LH up to 10-fold in the early postmenopausal years. FSH rises first and more steeply because the ovaries also stop producing inhibin B, a peptide that selectively suppresses FSH at the pituitary. LH rises later and less dramatically because it responds primarily to estrogen feedback rather than inhibin.
The FSH elevation has clinical utility as a diagnostic marker (FSH above 30-40 IU/L on two measurements taken at least one month apart is a standard criterion for confirming menopause), but it also has direct biological consequences beyond its role in the reproductive axis. FSH receptors exist on bone cells, adipocytes, and endothelial cells. A growing body of preclinical evidence suggests that elevated FSH itself (independent of estrogen decline) contributes to bone loss by promoting osteoclast formation and activity, drives visceral fat accumulation by influencing adipocyte lipid storage, and accelerates cardiovascular remodeling through direct effects on endothelial cells. The relative contributions of FSH elevation versus estrogen decline to these outcomes remains an active and unresolved debate.
The gonadotropin surge is not static. FSH and LH levels peak in the first 2-3 years after the final menstrual period, then gradually decline over subsequent decades (though they remain elevated compared to premenopausal levels throughout the postmenopausal lifespan). The initial peak likely reflects the most severe mismatch between hypothalamic drive and absent ovarian feedback. Clinically, this means the early postmenopausal years represent the period of maximum gonadotropin-driven tissue effects, including the most rapid phase of bone loss.
AMH: The Earliest Peptide Biomarker to Fall
Anti-Mullerian hormone is a peptide produced exclusively by small antral follicles in the ovaries. Because the number of remaining follicles determines AMH output, AMH levels decline steadily across reproductive life and reach undetectable levels 5-10 years before the final menstrual period. This makes AMH the earliest peptide biomarker of the menopausal transition, falling before FSH rises, before menstrual irregularity begins, and before any symptoms appear.
AMH's clinical value lies in this predictive lead time. Women with low AMH for their age can anticipate earlier menopause, which has implications for fertility planning, cardiovascular risk assessment, and bone health monitoring. However, AMH is not a perfect predictor of menopause timing at the individual level. The rate of AMH decline varies between women, and a single measurement provides only a snapshot.
After menopause, AMH is essentially zero and has no known direct clinical role in postmenopausal health monitoring. Its relevance is entirely in the years leading up to the transition, where it serves as a real-time readout of remaining ovarian reserve. In the context of IVF, AMH levels guide stimulation protocol selection and dosing, as detailed in the article on AMH as a fertility biomarker. The trajectory of AMH decline across a woman's 30s and 40s provides more information than any single measurement: a rapid decline suggests accelerated follicle loss and earlier menopause, while a slow decline suggests preserved reserve. Research into whether the rate of AMH decline predicts the severity of menopausal symptoms (not just their timing) is ongoing but preliminary.
Growth Hormone and the GH-IGF-1 Axis
Growth hormone (GH) secretion declines approximately 14% per decade in adult life, a process called somatopause. Menopause accelerates this decline through the loss of estrogen's amplifying effect on the peptide signals that drive GH release.[10]
Two peptide secretagogues control GH release from the pituitary: growth hormone-releasing hormone (GHRH) from the hypothalamus and ghrelin from the stomach. In premenopausal women, estrogen amplifies the pituitary's response to both peptides. After menopause, this amplification disappears.[11] Studies using dual secretagogue infusion (GHRH plus GH-releasing peptide) show that postmenopausal women release less GH per pulse than premenopausal women at every combination of secretagogue doses tested.
The downstream consequence: insulin-like growth factor 1 (IGF-1) levels fall. IGF-1 mediates most of GH's effects on muscle mass, bone density, and metabolic rate. The combined loss of estrogen and GH/IGF-1 signaling contributes to sarcopenia, increased visceral adiposity, and reduced bone formation that characterize the postmenopausal state.
Estradiol supplementation partially restores the GH response to GHRH and ghrelin in postmenopausal women, demonstrating that the deficit is not from irreversible pituitary aging but from the loss of estrogen's permissive effect on peptide-driven GH release.[11]
Bone Peptides: Calcitonin, PTH, CGRP, and Collagen Markers
Postmenopausal bone loss involves shifts in multiple peptide systems that regulate the balance between bone formation and resorption.
Calcitonin, a 32-amino-acid peptide from thyroid C-cells, inhibits osteoclast-mediated bone resorption. Calcitonin levels decline after menopause, partially removing this brake on bone breakdown. Calcitonin nasal spray was once a common osteoporosis treatment, though it has largely been replaced by more effective agents.
Parathyroid hormone (PTH) levels tend to rise modestly after menopause, driven partly by declining calcium absorption and declining vitamin D levels. The relationship between PTH and bone in postmenopause is complex: continuous PTH elevation drives resorption, but pulsatile PTH administration (as in teriparatide and abaloparatide) stimulates bone formation. Abaloparatide reduced new vertebral fractures by 86% compared to placebo over 18 months in postmenopausal women with osteoporosis.[9]
Neuropeptides in bone tissue undergo measurable changes after menopause. A 2018 study found that substance P (SP), calcitonin gene-related peptide (CGRP), vasoactive intestinal peptide (VIP), and neuropeptide Y (NPY) all shift in postmenopausal osteoporotic bone tissue.[7] SP and CGRP (which promote osteoblast activity and bone formation) were reduced, while NPY (associated with bone resorption) was elevated. These neuropeptide changes may represent an underappreciated mechanism of postmenopausal bone loss beyond the well-established estrogen-osteoclast pathway.
Collagen peptides as oral supplements have shown modest bone-building effects in postmenopausal women. A 2018 randomized controlled trial found that 5 g/day of specific collagen peptides over 12 months increased bone mineral density at the femoral neck and lumbar spine compared to placebo in postmenopausal women.[8] These peptides are not hormones but bioactive fragments that may stimulate osteoblast differentiation.
Cardiovascular Peptides: CGRP and Natriuretic Peptides
Cardiovascular risk increases after menopause, and peptide hormone changes contribute to this shift beyond the loss of estrogen's direct vascular effects.
CGRP (calcitonin gene-related peptide) is a potent vasodilator. Studies show that menopausal status affects circulating CGRP levels, with implications for both vascular tone and the migraine patterns that often change around menopause. CGRP also plays a role in hot flashes: vasodilation in the skin during flushes involves CGRP release, connecting the thermoregulatory peptide cascade (neurokinin B in the hypothalamus) to the peripheral vascular response.
Natriuretic peptides (ANP and BNP) regulate blood pressure, fluid balance, and cardiac remodeling. NT-proBNP, a fragment released when the heart produces BNP under stress, has been associated with early menopause and incident heart failure in postmenopausal women in large cohort studies including the ARIC (Atherosclerosis Risk in Communities) and MESA (Multi-Ethnic Study of Atherosclerosis) cohorts. Women who experienced menopause before age 45 had higher NT-proBNP levels and elevated heart failure risk compared to women with later menopause, suggesting that longer duration of estrogen deprivation worsens cardiac peptide signaling. The relationship is bidirectional: estrogen loss may directly alter natriuretic peptide synthesis and receptor expression in the heart, and natriuretic peptide system impairment (demonstrated in FSH receptor knockout mice) may worsen hypertension risk after menopause through impaired sodium excretion and vascular tone regulation.
Metabolic Peptides: GLP-1, Insulin, and Ghrelin
The metabolic peptide landscape shifts after menopause in ways that promote weight gain, insulin resistance, and visceral fat accumulation.
GLP-1 (glucagon-like peptide-1) is an incretin peptide released from gut L-cells after eating. Estrogen modulates GLP-1 secretion, and some evidence suggests reduced incretin response after menopause. GLP-1 receptor agonists (semaglutide, tirzepatide) are increasingly used in postmenopausal women for weight management, though their effects on bone density in this population require long-term monitoring.
Ghrelin, the hunger hormone from the stomach, interacts with the menopausal hormone milieu. Ghrelin's GH-stimulating effect is blunted in postmenopausal women compared to premenopausal women, contributing to the GH/IGF-1 decline described above.[10] Ghrelin also signals through the hypothalamic circuits that overlap with the reproductive peptide network, creating potential interactions between appetite regulation, GH secretion, and reproductive hormone changes during the menopausal transition.
Insulin resistance increases after menopause independent of aging and weight gain. The mechanism involves estrogen's loss of insulin-sensitizing effects on skeletal muscle and hepatic glucose output, but peptide hormone changes compound the metabolic shift substantially. Reduced GH and IGF-1 decrease lean muscle mass (the body's primary glucose disposal tissue), altered ghrelin signaling affects both appetite and metabolic rate, and potentially reduced incretin responsiveness further impairs postprandial glucose handling. The convergence of these peptide changes across multiple organ systems helps explain why type 2 diabetes risk rises sharply after menopause, and why weight gain during the menopausal transition is disproportionately visceral (abdominal) rather than subcutaneous.
Sexual Function Peptides: Oxytocin and Bremelanotide
Peptide systems involved in sexual function also change across the menopausal transition.
Oxytocin, a 9-amino-acid peptide, is involved in orgasm, pair bonding, and vaginal lubrication. Basal oxytocin levels do not necessarily decline with menopause, but the tissue responsiveness to oxytocin in the genital tract may change with estrogen withdrawal. Exogenous oxytocin is being investigated for genitourinary syndrome of menopause, though evidence remains preliminary.
Bremelanotide (PT-141), a melanocortin-4 receptor agonist, was approved in 2019 for hypoactive sexual desire disorder in premenopausal women.[12] A randomized placebo-controlled trial demonstrated increased sexual desire and decreased distress from low desire. Its mechanism operates through central nervous system melanocortin pathways rather than peripheral hormone replacement, which makes it mechanistically distinct from estrogen-based approaches. Clinical development for postmenopausal women is ongoing, as the central mechanisms bremelanotide targets persist regardless of ovarian function.
The Therapeutic Landscape: Peptide-Targeted Interventions
The mapping of menopause's peptide cascade has produced one approved non-hormonal drug and several more in development:
Fezolinetant (Veozah, FDA-approved May 2023): a neurokinin 3 receptor antagonist that blocks neurokinin B signaling in KNDy neurons, reducing hot flash frequency by 50-60% in phase 3 trials without affecting estrogen levels. This drug validates the KNDy hypothesis of menopausal vasomotor symptoms. For details, see the dedicated article on fezolinetant.
Abaloparatide and teriparatide: PTH-related peptide drugs that build bone in postmenopausal women by exploiting the anabolic effect of pulsatile PTH receptor activation. Abaloparatide is the newer analog with a potentially more favorable safety profile.
Kisspeptin-based approaches: experimental, targeting the upstream peptide driver of both gonadotropin surges and vasomotor symptoms. See kisspeptin and hot flashes for the current research.
GLP-1 receptor agonists: not developed for menopause per se, but increasingly prescribed to postmenopausal women for obesity and metabolic syndrome. Their effects on bone density, lean muscle mass, and the GH-IGF-1 axis in estrogen-depleted women are not yet characterized by long-term data. The GLP-1 and sarcopenia risk may be particularly relevant in postmenopausal women already experiencing accelerated muscle loss.
The GnRH antagonists used in IVF and the GnRH agonists used in endometriosis represent a different therapeutic strategy: deliberately inducing a menopause-like state by suppressing the GnRH axis. Understanding the full peptide cascade of natural menopause informs how these iatrogenic menopause states should be managed.
Limitations and What Remains Unknown
Most of what we know about peptide hormone changes during menopause comes from cross-sectional studies comparing pre- and postmenopausal women at a single time point. True longitudinal data tracking the same women through the menopausal transition are limited, especially for hypothalamic peptides that cannot be measured directly in living humans (most KNDy neuron data come from autopsy studies or indirect peripheral measurements).
The relative timing of different peptide changes is poorly characterized. AMH clearly falls first, but when exactly do the neuropeptide shifts in bone tissue begin relative to GnRH frequency changes or GH decline? The answer matters for therapeutic timing but remains unknown.
Individual variation is enormous. Some women experience dramatic hot flashes (indicating robust KNDy hyperactivity) while others have none. Some lose bone rapidly while others maintain density for years. The peptide cascade described here represents the population average, not any individual woman's trajectory. What drives this variability at the molecular level remains largely unexplored, though genetic variation in peptide receptor expression is one plausible mechanism.
The interaction between menopausal peptide changes and metabolic peptide changes (GLP-1, insulin, ghrelin) is an early research area. Most studies have examined these systems in isolation. How the reproductive peptide cascade interacts with the metabolic peptide cascade to produce the cardiometabolic risk profile of postmenopause is only beginning to be mapped.
The Bottom Line
Menopause triggers a cascade of peptide hormone changes that extends from hypothalamic KNDy neurons through pituitary gonadotropins to bone, cardiovascular, metabolic, and sexual function peptide systems. The loss of ovarian estrogen and inhibin removes feedback constraints across these interconnected networks, producing the characteristic 15-fold FSH surge, KNDy neuron hypertrophy driving hot flashes, accelerated GH decline, bone peptide shifts favoring resorption, and metabolic peptide changes promoting insulin resistance. The neurokinin B pathway has already yielded the first non-hormonal drug for hot flashes (fezolinetant), and understanding the broader cascade is opening therapeutic targets from bone-building PTH analogs to kisspeptin-based interventions.